Distributor inventory | Tablet

Management of type 2 diabetes mellitus (especially post‑prandial/high after-meal blood sugar) as an adjunct to diet and exercise; used alone or with other antidiabetic medicines.

Voglibose is an alpha‑glucosidase inhibitor that delays digestion and absorption of carbohydrates in the small intestine. This reduces the rise in blood glucose after meals and helps improve overall glycaemic control.

Tablet for oral use. Usually taken just before the start of each main meal (or with the first bite of food) as prescribed. If you skip a meal, skip the dose. Follow diet/exercise plan; monitor blood glucose regularly.

Flatulence,abdominal bloating,abdominal pain,diarrhoea,nausea

May cause gastrointestinal side effects due to fermentation of undigested carbohydrates. Risk of hypoglycaemia increases when used with insulin or sulfonylureas—if low sugar occurs, treat with oral glucose (dextrose) rather than sucrose/table sugar. Use with caution in liver disease; periodic liver function monitoring may be advised. Avoid/use with caution in inflammatory bowel disease, intestinal obstruction, colonic ulceration, or chronic intestinal disorders. Not indicated for type 1 diabetes or diabetic ketoacidosis.

Insulin and sulfonylureas (increased risk of hypoglycaemia),other antidiabetic medicines (additive glucose-lowering),intestinal adsorbents and digestive enzyme preparations (may reduce effect),warfarin (monitor if used together),alpha-glucosidase inhibitors with laxatives (may worsen diarrhoea)

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Voglibose 0.3 mg Tablet (generic),Voglib 0.3 Tablet,Volibo 0.3 Tablet,Voglinorm 0.3 Tablet,Voglice 0.3 Tablet